BrainsWay treatment for Smoking Addiction - Manual
BrainsWay provides a patient manual for using Deep TMS as an aid in short-term smoking cessation.

BrainsWay partners with clinical practices to deliver patented H-Coil Deep TMS devices for depression, OCD, and smoking addiction.
brainsway.comCrawled Nov 12, 2026
BrainsWay provides a patient manual for using Deep TMS as an aid in short-term smoking cessation.
BrainsWay offers a patient manual for Deep TMS treatment of depression.
The page lists qualified depression treatment providers in Chicago and describes BrainsWay Deep TMS for Major Depressive Disorder.
The page lists qualified depression treatment providers in New York City and describes BrainsWay Deep TMS for Major Depressive Disorder.
The page lists qualified smoking addiction treatment providers in Houston and describes BrainsWay Deep TMS for smoking addiction.
BrainsWay's comprehensive partnership program allows mental health practitioners to feel secure in offering patients safe, effective and in-demand treatments.
A randomized controlled feasibility and safety study of deep transcranial magnetic stimulation - BrainsWay
BrainsWay provides cleaning recommendations for Deep TMS providers to help prevent COVID-19 spread.
Visit BrainsWay's Knowledge Center for all things Deep TMS: learn about clinical research, active trials, articles on the field of mental health, and more.
Deep Repetitive Transcranial Magnetic Stimulation Associated with Improved Social Functioning in a Young Woman withan Autism Spectrum Disorder.
A pilot study reviews the effects of Deep Repetitive Transcranial Magnetic Stimulation with H-coil on lower limb motor function after a stroke.
In times of crisis, it's crucial to stay safe and well-informed about COVID-19 developments.
BrainsWay’s Deep TMS treatment helps patients achieve wellness, with reimbursement support available.
TMS treatment costs depend on the condition, session number, and insurance coverage.
Deep Transcranial Magnetic Stimulation is a non-invasive procedure reimbursed by many insurers based on the strength of clinical data and FDA clearance.
BrainsWay offers several payment options for mental health practitioners looking to cover TMS equipment and provide patients with more comprehensive care.
Gavriel Magen serves as a board director at BrainsWay Deep TMS.
Dr. George is an expert in the use of brain imaging and stimulation to understand depression and devise new antidepressant treatments.
Dr. David Zacut has served as BrainsWay’s Chairman of the Board of Directors since the company’s inception.
R. Scott Areglado has served as Senior Vice President and Chief Financial Officer (CFO) at BrainsWay since May 2021.
As one of BrainsWay’s founders, Dr. Roth has served as the company’s Research & Development Manager & Chief Scientific Officer since May 2006.
Orly Uri was appointed as a director at BrainsWay in December 2018.
BrainsWay’s Deep TMS technology and staff support brain disorder treatment for patients worldwide.
BrainsWay’s Deep TMS technology offers a new approach to treating brain disorders.
BrainsWay’s Deep TMS provides noninvasive treatment options for depression, OCD, and smoking addiction.
BrainsWay releases its third-quarter 2026 financial results, detailing revenue growth and operational updates. The company highlights progress in its non-invasive neuromodulation therapies for mental health conditions. Key metrics and strategic initiatives are outlined in the earnings report.
BrainsWay expands U.S. insurance coverage for its Deep TMS™ therapy to over 118 million lives, enabling broader access for patients with obsessive-compulsive disorder (OCD). The company’s noninvasive brain stimulation technology gains wider reimbursement across multiple medical policies. This move supports increased adoption of Deep TMS™ as a treatment option for OCD patients nationwide.
BrainsWay demonstrates an **83.3% response rate** and **50% remission rate** in depressive symptoms among patients with depression and early-stage Alzheimer’s disease using its **Deep TMS™ therapy**. The peer-reviewed pilot study also reveals **measurable neurophysiological changes** in brain activity and connectivity following treatment. Researchers observe tangible improvements in patient outcomes linked to the non-invasive neuromodulation approach.
BrainsWay reports a **35% year-over-year revenue increase** in Q2 2026, reaching **$17.1 million**. The company highlights continued growth in its non-invasive brain stimulation solutions, driven by expanding adoption in clinical and research settings. Financial results reflect strong operational momentum amid ongoing demand for its proprietary technology.
We are sorry, the page you requested cannot be found. Please check the URL or visit our Homepage.
BrainsWay expands FDA clearance for its Deep Transcranial Magnetic Stimulation (Deep TMS™) system to include adolescents aged 15–21 as an adjunct therapy for major depressive disorder (MDD). The noninvasive neurostimulation treatment is now approved for a younger patient demographic, broadening access for those with treatment-resistant depression. BrainsWay specializes in advanced mental health interventions.